• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

User Fee Collections (FY 2010)

Back to Table of Contents: FY2010 ADUFA Financial Reports

 

ADUFA specifies that user fees shall be collected for certain animal drug applications and supplements upon their submission, and annual fees shall be collected for certain products, establishments, and sponsors. The statute also specifies the amount FDA is allowed to collect for each of these categories, and how the fee rates should be adjusted in each fiscal year for increases in workload.
 
Under ADUFA, fees collected and appropriated, but not spent by the end of a fiscal year, continue to remain available for FDA to spend in future fiscal years.  The balances carried forward from year to year are described on page 7.
 
Table 1 provides a breakout of user fees collected by fee category during the past two fiscal years, and also reflects the amount of open receivables. 
 
TABLE 1
Statement of Animal Drug User Fee Collections
and Receivables by Fee Sources
As of September 30, 2010
 
Fees Collected
FY 2009
FY 2010
Application Fees
$1,970,400
$3,557,400
Product Fees
$3,866,125
$4,620,195
Establishment Fees
$3,520,703
$4,357,150
Sponsor Fees
$3,468,327
$3,410,692
TOTAL COLLECTIONS
$12,825,555
$15,945,437
 
 
 
Fees Receivable
 
 
Product Fees
$0
$0
Establishment Fees
$0
$0
Sponsor Fees
$356,414
$529,208
TOTAL RECEIVABLES
$356,414
$529,208
Numbers may not add due to rounding to the nearest dollar.
 
User fee collections are reported in the year the fee was originally due—referred to as cohort years.  For example, a fee originally due in FY 2009, even if it is received in FY 2010, is attributed to FY 2009 collections.  In FY 2010, total fee collections for FY 2009 of $12,904,435 reported in last year’s financial report decreased to $12,825,555 as of September 30, 2010. 
 
The receivables for FY 2009 and FY 2010 are from uncollected product, establishment, and sponsor fees. After 90 days of attempting to collect the delinquent debt, FDA turns these receivables over to the Program Support Center (PSC) of the Office of the Secretary for further attempts at collection.  After 180 days of the debt being outstanding, PSC will turn the debt over to the United States Treasury for further collection efforts.
 
Totals reported for each fiscal year are net of any refunds for that year.  In order to ensure the quality of the information provided in this financial report, FDA updates prior year collections and receivables each year.

 

Next Section: User Fee Obligations